IGKV2D-29 and amyotrophic lateral sclerosis: Despite the growing body of evidence for increased adenosine levels and upregulation of A2AR levels in human ALS and ALS models (Table 2), pharmacological outcomes, using both A2A agonists/antagonists, vary considerably (Table 3).